Ultrasound data of a variety of liver masses
收藏资源简介：
Data was generated as part of two ongoing clinical trials investigating the use of contrast-enhanced ultrasound to a) characterize indeterminate liver lesions and b) monitor treatment response to loco regional therapy. Ultrasound data was obtained on a variety of state of the art ultrasound scanners with curvilinear probes. Gain, dynamic range, focus position and depth were optimized for image quality by the performing sonographer. Images of the mass in both sagittal and transverse planes were obtained and saved in DICOM format. Full cine-loops of the contrast enhanced ultrasound are also saved in DICOM format. The reference standard used for lesion characterization included tissue pathology and contrast-enhanced cross-sectional imaging within 1 month of the ultrasound exam. The initial treatment response to transarterial chemoembolization is also available for many HCC cases and uses pathology, retreatment angiography, or longer-term tumor response on cross-sectional imaging as a reference standard. We expect these images can be used in a wide variety of image processing application. We are currently exploring a variety of automated intelligence algorithms for AI-based lesion characterization. Algorithms for object detection and segmentation may also be of interest. As the studies that have generated this data are also ongoing, it is expected that we can add volumetric data, contrast-enhanced ultrasound cine loops, and longer-term treatment response data to this data set in the future.
本数据集源自两项正在进行的临床试验，旨在探究增强超声（Contrast-Enhanced Ultrasound）的两项应用：a）定性不确定性质的肝脏病变；b）监测局部区域治疗的应答效果。研究采用多款当前最先进的超声扫描仪搭配凸阵探头采集超声数据，操作超声医师会针对图像质量优化增益、动态范围、聚焦位置及扫描深度。研究获取了病灶在矢状位及横断位的影像，并以DICOM格式存储；完整的增强超声动态循环序列同样以DICOM格式保存。用于病变性质判定的参考标准包括超声检查1个月内获取的组织病理学结果及增强型横断面成像结果。针对多数肝细胞癌（Hepatocellular Carcinoma, HCC）病例，还可获取其经动脉化疗栓塞（Transarterial Chemoembolization）的初始治疗应答数据，其参考标准包括病理学结果、再次治疗血管造影结果，或横断面成像显示的长期肿瘤应答情况。我们预期该数据集影像可应用于多种图像处理任务，目前团队正探索基于人工智能（AI）的病变性质判定相关的各类智能算法，目标检测与分割相关算法同样具有研究价值。由于生成该数据集的两项临床试验仍在进行中，预计未来可向本数据集补充体数据、增强超声动态循环序列及长期治疗应答数据。
